• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Combining Immunotherapies Shrinks Melanoma Tumors

Article

Researchers at the University of Pennsylvania's Abramson Cancer Center found combining 2 immunotherapies to be safe and elicit a clinical response in patients with metastatic melanoma.

Researchers at the University of Pennsylvania’s Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. The first-of-its-kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial presented at the American Association for Cancer Research Annual Meeting 2015.

Researchers include first author David L. Bajor, MD, instructor of medicine in the division of hematology/oncology, and senior author Robert H. Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research.

“We’ve had wonderful success with immunotherapies, but we are barely scratching the surface,” Dr Bajor said.

Read the press release from Penn Medicine: http://bit.ly/1GbHx8d

Related Videos
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Raajit Rampal, MD, PhD, screenshot
Ronesh Sinha, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.